Hematology News

In this video, Allyson Pishko, MD, MSCE, spoke with Healio about data from the ASH Annual Meeting and Exposition on COVID-19 and the safety of the vaccines in regard to the risk for deep vein thrombotic events.

In this video, Allyson Pishko, MD, MSCE, highlighted two studies from ASH Annual Meeting and Exposition that investigated fitusiran (Sanofi) as treatment for both hemophilia A and B.

According to a meta-analysis of three studies, prolonged TV viewing was associated with elevated risk for venous thromboembolism, independent of traditional risk factors, including age, sex, BMI and physical activity.

ASH recognized three Choosing Wisely Champions during the ASH Annual Meeting and Exposition, held last month in Atlanta.

Individuals with an increased platelet count demonstrated an increased risk for cancer, with the association especially strong in colon, lung, ovarian and stomach cancers, according to a nested case-control study in JAMA Network Open.

Among patients with nonvalvular atrial fibrillation, those with frailty were less likely to receive an anticoagulant and, if anticoagulated, were more likely to receive warfarin than a direct oral anticoagulant, researchers reported.

Among young patients with provoked venous thromboembolism, shorter duration of anticoagulation is noninferior to current standard of care, according to the results of the Kids-DOTT randomized trial.

Eltrombopag increased response rates when added to standard immunosuppressive therapy among patients with transplant-ineligible severe aplastic anemia, according to phase 3 study results published in The New England Journal of Medicine.

The FDA announced it has authorized marketing of the first laser-based device for the removal of inferior vena cava filters.

Anticoagulation with rivaroxaban for patients with atrial fibrillation aged 65 years or more was associated with greater risk for major ischemic and hemorrhagic events compared with apixaban, according to data published in JAMA.